Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05431634 · ClinicalTrials.gov registry record · Phase 1
Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants
A Phase 1 study, sponsored by Alumis.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT05431634 is a Phase 1 study that has completed, run by Alumis. The registered enrollment target is 49 participants.
The verdict
NCT05431634, a Phase 1 study, has completed, sponsored by Alumis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
Multiple Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ESK-001 in Healthy Participants
Interventions
- OTHER Placebo
- DRUG Experimental drug: ESK-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2022-05-12 |
| Est. Completion | 2022-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05431634
The ClinicalTrials.gov registry entry for NCT05431634 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alumis, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05431634 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05431634 about?
NCT05431634 is a clinical study titled "Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants". Multiple Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ESK-001 in Healthy Participants
What is the current status of trial NCT05431634?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2022-05-12. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT05431634?
The interventions under investigation include: Placebo (OTHER), Experimental drug: ESK-001 (DRUG).
Who is sponsoring clinical trial NCT05431634?
This trial is sponsored by Alumis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.